Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Fast Track designation indicates LBS-007’s potential in filling the unmet medical need of acute leukemiaLBS-007 is the Company’s investigational medicinal product for the treatment of acute leukemiaA Phase 1/2 trial in patients with relapsed or resistant acute leukemias is ongoingLBS-007, the Company’s lead asset, has been granted orphan drug designations for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScienc